pretickt

Is INCY a good stock to buy?

Incyte Corporation · end-of-day data as of Nov 13, 2026

Incyte
INCY · $24.66B
$120.97-0.6%
Nov 13, 2026 · close
$110$120$130SepOctNov9:3016:003 months -2.0%Nov 13 · close
▲ 4
  • PT$132.79 +9.8%
  • MAs4 of 4
  • MACD0.56
  • Sector▲ +15.9%
Neutral
  • Earnings in88d
  • P/E64.3x
  • RSI54
  • Support-3.3%
  • Resistance+0.8%
  • Off 52w high-8.8%
  • Volume0.5x
  • Bollingerupper half
  • News0.00
  • FCF yield+2.8%
  • ConsensusHold · 29
  • Trendsideways
  • 52w range$89–$133
  • ATR+3.2%
  • Off ATH-21.0%
  • MA20×50↑ in ~2d
▼ 3
  • P/E vs own+139.0%
  • P/E vs sector+99.7%
  • Insiders-$32.96M

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Incyte a good stock to buy?

Incyte is strong on 3 of the 5 questions about the business; weak on fragility. The price is high: 64.3 times its earnings, above its 3-year median of 20.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage hard to copy
  3. Economics profits growing
  4. Execution mixed
  5. Fragility fragile
  6. Price expensive
DemandDo people want more of what it sells?growing

INCY sales growth revenue growth

+15%a year, for the last 3 years

Incyte's sales grew 15% a year for 3 years, to $5.14B in fiscal 2025.

INCY analysts' forecast revenue estimates

+18%the sales they expect next fiscal year, on the last

Analysts expect Incyte's sales to grow 18% to $6.04B in fiscal 2026 (17 analysts).

INCY competitors

pretickt analysis+25%its sales in 12 months, on a year before

Incyte's sales grew 25% in the 12 months to Sep 30, 2026, faster than Twist Bioscience (+22%), Moderna (+14%) and Bio-Techne (+1%), slower than Alnylam (+56%).

Advantage moatIs it hard to copy?hard to copy

INCY margin on each sale gross margin

93%left after making the product

Incyte kept 93% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 59%.

EconomicsDoes it make good money?profits growing

INCY cash generated free cash flow

$685Mcash left after investing, last 12 months

Incyte generated $685M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

INCY profit per share

+2,274%in its last fiscal year

Incyte's earnings per share grew 2,274% in fiscal 2025, to $6.41.

ExecutionDoes it deliver what it promises?mixed

INCY earnings vs estimates

6 of 8quarters above the analysts' estimate

Incyte beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Oct 29, 2026.

INCY insider selling

-$66.11Msold, net, by its executives in 12 months

Incyte's executives and directors sold a net $66.11M of shares in the 12 months to Nov 13, 2026; none bought.

INCY number of employees

+9%more people in a year

Incyte had 2,844 employees at the end of fiscal 2025, 9% more than a year before.

INCY CEO pay

$32.09Mfor fiscal 2025, 94% of it in stock and options

Incyte paid its CEO $32.09M for fiscal 2025, 94% of it in stock and options.

Fragility risksCould something break it?fragile

INCY financial health Altman Z-score

10.9Altman Z-score, safe above 3

Incyte's Altman Z-score is 10.9 (Nov 13, 2026), above 3, where the safe zone starts.

INCY quality checks Piotroski score

6 of 9checks passed

Incyte passes 6 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, new shares and gross margin.

INCY biggest customers

63%of sales from its 4 biggest customers

Four customers, unnamed in Incyte's 10-K, made 63% of its sales in fiscal 2025.

INCY in past recessions

pretickt analysis-89%its sales in the worst one

Incyte's sales fell in 1 of the last 2 US recessions, by as much as 89% in fiscal 2008.

Price valuationIs the price reasonable?expensive

INCY price vs profit P/E ratio

64.3×a year's earnings

Incyte's P/E ratio is 64.3 (Nov 13, 2026), above its 3-year median of 20.5.

INCY price vs competitors

pretickt analysis64.3×a year's earnings, against its competitors

Investors pay 64.3 times Incyte's earnings (Nov 13, 2026), more than for Alnylam (8.3), less than for Bio-Techne (66.2).

INCY analysts' target price target

+10%to their average target

Analysts' average price target for Incyte is $133, 10% above the Nov 13, 2026 close of $120.97.

INCY analyst ratings, 90 days

pretickt analysis
  • Oppenheimerupgrade
1 up, 0 downratings raised and cut

In the 90 days to Nov 13, 2026, Oppenheimer upgraded Incyte.

INCY growth priced in fair value

pretickt analysis+15%a year, for ten years, to be worth the price

At $120.97 a share, Incyte's free cash flow must grow about 15% a year for ten years to be worth the price (Nov 13, 2026).

What is Incyte's P/E ratio?

Incyte's P/E ratio is 64.3 (Nov 13, 2026), above its 3-year median of 20.5. Investors pay 64.3 times Incyte's earnings (Nov 13, 2026), more than for Alnylam (8.3), less than for Bio-Techne (66.2).

Who are Incyte's biggest competitors?

pretickt compares Incyte with Alnylam, Bio-Techne, Twist Bioscience and Moderna. Incyte's sales grew 25% in the 12 months to Sep 30, 2026, faster than Twist Bioscience (+22%), Moderna (+14%) and Bio-Techne (+1%), slower than Alnylam (+56%).

Are insiders selling Incyte stock?

Incyte's executives and directors sold a net $66.11M of shares in the 12 months to Nov 13, 2026; none bought.

How many employees does Incyte have?

Incyte had 2,844 employees at the end of fiscal 2025, 9% more than a year before.

Who are Incyte's biggest customers?

Four customers, unnamed in Incyte's 10-K, made 63% of its sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.